Landos Biopharma is a late clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases. Leveraging our AI-based integrated computational platform, LANCE, we have identified seven novel clinical and preclinical candidates across various areas of unmet medical need. Our lead product candidate, omilancor (BT-11), is a small molecule targeting Lanthionine Synthetase C-Like 2 (LANCL2), a pathway designed to limit its impact to the gastrointestinal tract. In 2021, the Company reported final results from a Phase 2 proof-of-concept trial of omilancor in patients with mild-to-moderate ulcerative colitis (UC) and is preparing to initiate a global pivotal Phase 3 program of omilancor in UC patients. Additionally, Landos initiated a Phase 2 trial of omilancor for the treatment of moderate-to-severe Crohn’s disease (CD) in May 2021.
The Company’s mission is to create safer and more effective treatments that address the therapeutic gap in the current treatment paradigm for autoimmune disease.